Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03466216
Other study ID # ALPHAMEDIX01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date February 5, 2018
Est. completion date July 1, 2022

Study information

Verified date August 2021
Source Radiomedix, Inc.
Contact Susan Cork
Phone 713-781-6200
Email scork@exceldiagnostics.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

AlphaMedix™ (²¹²Pb-DOTAMTATE) is a radiotherapeutic drug indicated in subjects with unresectable, metastatic somatostatin receptor (SSTR) positive neuroendocrine tumors (NETs). Because 212Pb is an in vivo generator of alpha particles, it is particularly suitable for SSTR therapy applications. This drug addresses an unmet need in the field of peptide receptor radionuclide therapy (PRRT) for NETs. Substitution of an alpha emitter (²¹²Pb) for the beta emitters currently being used (i.e., 177Lu or 90Y) will provide significantly higher Linear Energy Transfer (LET) and a shorter path length. Higher LET particles should cause more tumor cell death. Shorter path length should result in less collateral damage of the normal tissue and therefore less side effects for subjects receiving the drug.


Description:

This dose escalation study will include a maximum of 50 subjects with histologically confirmed NET, a positive somatostatin analogue scan, and no prior history of PRRT therapy. The study will begin with a single ascending dose (SAD) of AlphaMedix™ administered by IV. Subsequent cohorts will receive an incremental 30% increase that will continue until tumor response or DLT. Once tumor response is observed, the study will convert to a Multiple Ascending Dose (MAD) regimen. The MAD treatment regimen will start with the previous safe cohort's dose and will consist of 3 IV administrations of AlphaMedix™ at 8-week intervals. Subsequent cohorts will receive an incremental 30% increase that will continue until tumor response or DLT. The primary objective is to assess the safety and dose limiting toxicity (DLT) using ascending doses of AlphaMedix™. The secondary objectives are to determine the pharmacokinetic properties and preliminary effectiveness of AlphaMedix™.


Recruitment information / eligibility

Status Recruiting
Enrollment 33
Est. completion date July 1, 2022
Est. primary completion date July 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - ECOG status 0-2. - Life expectancy of at least 12 weeks. - Histologically confirmed diagnosis of SSTR (+) NET, unresectable or metastatic. - Measurable disease per RECIST 1.1 on CT/MRI scans, defined as at least 1 lesion with = 1 cm in longest diameter (LD) (lymph nodes along short axis). - Appropriate diagnostic imaging studies, at the discretion of the PI including but not limited to CT, MRI, 18F-FDG PET/CT, NAF PET/CT bone scan, ultrasound, etc. of the tumor region or suspected area within the 4 weeks of dosing day. - SSTR(+) disease, as evidenced by available FDA approved SSTR imaging (SRI) within 4 weeks prior to the first cycle. - All FDA-approved therapies for which the subject is eligible have been exhausted. - Recent blood test results (within 2 weeks pre-dose) as follows: Sufficient bone marrow capacity as defined by white blood cell (WBC) =2,500/µl and WBC =2,000/µl for subsequent cycles; platelets = 100,000/µl for the first treatment and =75,000 for the subsequent therapies, hemoglobin (HgB) =8.9 g/dl for the first treatment and 8.0 g/dl for the subsequent therapies, ANC =1,500/µl for the first treatment and =1,000/µl; for the subsequent therapies; ALT, AST values =3 times upper limit of normal (ULN); Bilirubin: =3 times ULN; Serum creatinine =150 µmol/liter or 1.7 mg/dl; Negative pregnancy test in women capable of child-bearing within 48 hours of administration; Serum albumin > 3.0 g/L (<3.0 g/L may be acceptable at the discretion of PI, if PT, PTT, and INR are within normal range) Exclusion Criteria: - Prior whole-body radiotherapy and PRRT using 177Lu/90Y/111In- DOTATATE/DOTATOC or TAT - Known hypersensitivity to 68Gallium, Octreotate, or any of the excipients of 68Ga-DOTATATE, AA infusion or AlphaMedix™. - Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28 days) and Sandostatin® (within 1 day) prior to administration of investigational drug. - Subjects with unusual hematological parameters, including an increased mean corpuscular volume (MCV) (>100,000), and especially in those who had previous chemotherapy, the advice of a hematologist should be sought for adequate further work-up to rule out myelodysplastic syndrome (MDS). - Any subject who is taking concomitant medications that decrease renal function (such as aminoglycoside antibiotics). - Female subjects who are pregnant, lactating or women of childbearing potential not willing to practice effective contraceptive techniques during the study period and for 8 weeks post-injection or male subjects who have female partners of childbearing potential not willing to practice abstinence or effective contraception, during the study period and for 8 weeks post-injection. - Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study. - Indication for surgical lesion removal with curative potential - Known brain metastases; unless these metastases have been treated and stabilized 6 months prior to enrollment - Completion of: (1) cytotoxic chemotherapy for less than 6 weeks; (2) a biological agent for less than 5 half-lives; and (3) radiation therapy for less than 6 weeks prior to study enrolment, - Uncontrolled congestive heart failure; subjects suspected of having this condition need to show ejection fraction of >55% as determined by multigated acquisition (MUGA) scan. - Carcinoid heart disease: Prior history of torsade de pointe, or congenital long QT syndrome; Conditions with screening ECG repolarization difficult to interpret, or showing significant abnormalities. This includes, but is not limited to: high degree AV block, pacemaker, atrial fibrillation or flutter; QTcF interval > 480 msec on screening ECG; Significant hypokalemia at screening (Potassium <3.5 mMol/L); Significant hypomagnesemia at screening (Mg++ <0.7 mMol/L) - GFR < 35 mL/min

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AlphaMedix
There is only a single treatment intervention.

Locations

Country Name City State
United States Excel Diagnostics and Nuclear Oncology Center Houston Texas
United States Excel Diagnostics and Nuclear Oncology Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
Radiomedix, Inc. Orano Med LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine dose-limiting toxicity (DLT) DLT is defined as non-hematological toxicity - all Grade 4 and Grade 3 (except alk. phos.) that is not responsive to NMT 72 hours of supportive care - and all hematological toxicity that does not recover to NMT than Grade 2 within 8 wks of dose administration. 8 weeks
Primary To determine the maximum tolerated dose (MTD) The MTD is the dose level below that which 2 out of 6 subjects in a cohort have DLT. 8 weeks
Secondary Partial or complete response assessed by modified RECIST v1.1 CT/MRI or 18FDG-PET/CT (for patients who are FDG-avid at baseline) will be used to measure tumor size 8 weeks after injection
Secondary To determine effective blood clearance and cumulative blood activity of 212-Pb Blood will be taken at Time 0, 1 hr, 4 hr and 24 hr post-injection and measured for activity in an auto gamma counter 24 hours
Secondary To determine the rate and extent of 212-Pb elimination in urine Bladder will be emptied just prior to injection and qualitative urine collections will be done 0-1 hr, 1-4 hr and 4-24 hr post-injection and measured for activity in an auto gamma counter 24 hours
Secondary Incidence of treatment-related AEs and SAEs as assessed by CTCAE v. 4 AEs will be recorded both spontaneously by the patient and at all safety follow ups (2 wks, 4 wks, 6 wks, 8 wks post each injection and 3 mo, 6 mo, and 10 mo post last injection) 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04837885 - Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases Phase 2
Completed NCT00789841 - Gastrointestinal Motility in Patients With Neuroendocrine Tumors N/A
Recruiting NCT05069220 - 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor Early Phase 1
Completed NCT05816720 - Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Active, not recruiting NCT04400474 - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Phase 2
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Completed NCT01849523 - Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study N/A
Recruiting NCT01448083 - Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours N/A
Completed NCT00804336 - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Phase 1
Active, not recruiting NCT02092714 - Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
Terminated NCT04073017 - Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency N/A
Completed NCT00434109 - Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Phase 2
Completed NCT02472678 - Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor N/A
Completed NCT02481804 - Optimal Feeding for NET Patients N/A
Completed NCT02147106 - Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study
Completed NCT00165230 - Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors Phase 2
Active, not recruiting NCT03012789 - Surgical Intervention and the NETest N/A
Not yet recruiting NCT02038738 - 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors Phase 1/Phase 2
Completed NCT01024387 - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Phase 2
Terminated NCT00227617 - Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Phase 2/Phase 3